Hepatitis C Virus (HCV) Clinical Trial
— NeoVieOfficial title:
New Care Pathways to Achieve HCV Elimination in the Community: Real-world Outcomes From HCV Infected Patients Treated in Addiction Centers in France
NCT number | NCT04366973 |
Other study ID # | P20-127 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | May 26, 2020 |
Est. completion date | December 31, 2023 |
Verified date | January 2024 |
Source | AbbVie |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Hepatitis C Virus is liver disease and is a leading cause of death and morbidity with around 71 million people affected worldwide. Widespread availability of highly effective direct-acting antivirals (DAAs) have dramatically changed the treatment landscape of HCV with a cure rate of over 95%. In May 2019, French Health Authorities expanded prescription abilities to all physicians treating adult treatment-naive patients with HCV without cirrhosis of the liver. This study will assess the treatment uptake and barriers to treatment by non-HCV specialist in France in community-based addiction centers. Beyond these evaluations, data on health resource utilization in addiction centers, level of knowledge of both patients and providers on HCV infection and treatment, care cascade, effectiveness and safety of Glecaprevir/Pibrentasvir among patients treated in addiction centers and evolution of addiction behavior after treatment are of specific interest. Glecaprevir/Pibrentasvir is a drug approved to treat HCV. About 400 Adult participants with a confirmed positive HCV ribonucleic acid (RNA) test will be enrolled in the study at approximately 30 addiction centers in France. All participants will attend an inclusion visit. Participants who are not prescribed Glecaprevir/Pibrentasvir at the inclusion visit will have no further follow-up in the study. Participants who are prescribed Glecaprevir/Pibrentasvir will take three tablets once daily. The duration of the study is approximately 12 months. All study visits will occur during routine clinical practice but there may be a higher burden for participants prescribed Glecaprevir/Pibrentasvir. These participants will be asked to complete questionnaires after each visit.
Status | Completed |
Enrollment | 95 |
Est. completion date | December 31, 2023 |
Est. primary completion date | December 31, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Followed in an addiction center. - Confirmed positive for HCV ribonucleic acid (RNA). Exclusion Criteria: -None. |
Country | Name | City | State |
---|---|---|---|
France | Centre de Soins Accompagnement et de Prevention en Addictologie-Antibes /ID# 221277 | Antibes | |
France | Centre de soin d'accompagnement et de prevention en addictologie-Paul Guiraud /ID# 218710 | Bagneux | Ile-de-France |
France | CSAPA Bagnols sur ceze /ID# 233397 | Bagnols Sur Ceze | Gard |
France | Centres de Soin d'Accompagnement et de Prevention en Addictologie -Bayonne /ID# 218673 | Bayonne | |
France | CEID Bordeaux /ID# 221517 | Bordeaux | Gironde |
France | Centre Hospitalier Le Vinatier - Service universitaire d'addictologie de Lyon /ID# 218695 | Bron | Rhone |
France | CHU Clermont Ferrand - Hopital Gabriel Montpied /ID# 221278 | Clermont Ferrand | |
France | Centre de Soins Accompagnement et de Prevention en Addictologie - AGORA /ID# 223793 | Cognac | |
France | Centre de Soins Accompagnement et de Prevention en Addictologie - ARGILE /ID# 223792 | Colmar | |
France | Centre de Soins d'Accompagnement et de Prevention en Addictologie-ANPAA 21 /ID# 222909 | Fontaine-lès-Dijon | |
France | Centre de Soins Accompagnement et de Prevention en Addictologie-CICAT /ID# 221281 | Le Coudray | |
France | Centre de Soins Accompagnement et de Prevention en Addictologie-Boris Vian /ID# 221284 | Lille | Nord |
France | Centre Bobillot - Limoges /ID# 221922 | Limoges | |
France | Centre de Soins d'Accompagnement et de Prevention en Addictologie- Le Sémaphore /ID# 222954 | Marseille | |
France | Centres de Soin d'Accompagnement et de Prevention en Addictologie-Les WADS CMSEA /ID# 218671 | Metz | Moselle |
France | Centre de soins d'accompagnement et de prevention en addictologie-ANPAA 82 /ID# 218675 | Montauban | Occitanie |
France | Centre de soin d'accompagnement et prevention en addictologie-UTTD Montpellier /ID# 218683 | Montpellier | Herault |
France | Centre de Soins d'Accompagnement et de Prevention en Addictologie- Arc en ciel /ID# 218700 | Montpellier | Herault |
France | Centre de Soins d'Accompagnement et de Prevention en Addictologie- Le Cap /ID# 222776 | Mulhouse | |
France | Clinique Jules Verne /ID# 241666 | Nantes | |
France | Centre de soin d'accompagnement et de prevention en addictologie- CHU Archet 2 /ID# 218682 | Nice | Alpes-Maritimes |
France | Centre de Soins d'Accompagnement et de Prevention en Addictologie- Malaussena /ID# 218703 | Nice | |
France | Centre de soin d'accompagnement et de prevention en addictologie- L'ENVOL /ID# 218680 | Nimes | Gard |
France | Centre de Soins d'Accompagnement et de Prevention en Addictologie-Nova Dona /ID# 221516 | Paris | |
France | CSAPA CAARUD Aurore EGO /ID# 225050 | Paris | |
France | CEID Bearn addictions /ID# 221279 | Pau | |
France | Csapa Doaur Nevez de Ploermel /Id# 240583 | Ploermel | Morbihan |
France | Association Tremplin 17 - Saintes /ID# 218708 | Saintes | Nouvelle-Aquitaine |
France | Centre de soin d'accompagnement et de prevention en addictologie -ITHAQUE /ID# 218678 | Strasbourg | |
France | Centre de Soins d'Accompagnement et de Prevention en Addictologie-Tempo Oppelia /ID# 218701 | Valence | Drome |
Lead Sponsor | Collaborator |
---|---|
AbbVie |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of participants with and without Hepatitis C Virus (HCV) treatment prescribed at end of the inclusion visit. | Percentage of participants with and without HCV treatment prescribed at end of the inclusion visit. Criteria for treatment choice and reasons for treatment refusal will be described. | Inclusion visit (Week 0) | |
Secondary | Health Care Resources and Utilization | HCRU in the addiction centers will be described on the basis of declarative questionnaires completed at time of the study implementation (yearly number of people followed, health resources, staffing, formation of center team, capabilities regarding HCV screening, specialized consultations in hepatology, and liver fibrosis tests). | Inclusion visit (Week 0) | |
Secondary | Level of HCV infection knowledge | The level of knowledge of both patients and providers on HCV infection will be described on the basis of declarative questionnaires. For patients, analysis will be performed in the TP population and according to patient subgroups (with and without HCV treatment). | Inclusion visit (Week 0) | |
Secondary | Determinants associated with initiation of HCV treatment | Criteria for treatment choice or no treatment uptake assessed by physician, patient, and disease characteristics. | Inclusion visit (Week 0) | |
Secondary | Data and disease characteristics from patients with and without HCV treatment | Data and disease characteristics from patients with and without HCV treatment. | Inclusion visit (Week 0) | |
Secondary | Number of participants with HCV Antibodies (HCV Ab) | Number of participants with HCV Antibodies (HCV Ab). | Inclusion visit (Week 0) | |
Secondary | Number of participants with HCV RNA | Number of participants with HCV RNA. | Inclusion visit (Week 0) | |
Secondary | Time from HCV Ab to HCV RNA | Time from HCV Ab to HCV RNA. | Inclusion visit (Week 0) | |
Secondary | Time from HCV RNA to end of treatment | Time from HCV RNA to end of treatment. | Approximately 12 months | |
Secondary | Number of participants who completed treatment | Number of participants who completed treatment. | Approximately 12 months | |
Secondary | Percentage of participants achieving SVR12 | SVR12 defined as HCV RNA under the lower limit of quantification (LLOQ) 12 weeks after the last dose of treatment with a sensitive polymerase chain reaction (PCR) test. | Approximately 12 months | |
Secondary | Percentage of cured participants willing to share their experience with other substance abuse patients. | Percentage of cured participants willing to share their experience with other substance abuse patients at the SVR12 visit and up to 6 months after the SVR12 visit. | Approximately 12 months | |
Secondary | Number of participants achieving sustained viral response at 12 weeks (SVR12) | Number of participants achieving sustained viral response at 12 weeks (SVR12). | Approximately 12 months | |
Secondary | Time to SVR12 | Time to SVR12 | Approximately 12 months | |
Secondary | Number of people in charge of patient follow-up | Number of people in charge of patient follow-up including physicians, nurses, social workers. | Approximately 12 months | |
Secondary | Percentage of participants with treatment adherence | Defined as the percentage of participants who have taken the target dose according to participant reporting. | Approximately 12 months | |
Secondary | Patient Reported Quality of Life | Anxiety and depression questionnaires and global assessment using visual analog scale. | Approximately 12 months | |
Secondary | Number of participants with addictive behaviors | Addictive behaviors of participants (alcohol and drug consumption) will be assessed by participant-completed questionnaires. | Approximately 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02487199 -
Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir in Adults With Genotype 1a or Genotype 4 Chronic Hepatitis C Virus (HCV) Infection, With Severe Kidney Impairment or End Stage Kidney Disease
|
Phase 3 | |
Completed |
NCT03235349 -
Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive and Treatment-Experienced Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With Compensated Cirrhosis and With or Without Human Immunodeficiency Virus Co-Infection
|
Phase 3 | |
Completed |
NCT04577482 -
Study of Oral Glecaprevir/Pibrentasvir Tablets in Participants Aged 12 Years or Older With Chronic Hepatitis C to Assess Sustained Virological Response
|
||
Completed |
NCT03222583 -
A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive and Treatment-Experienced, Non-Cirrhotic Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With or Without Human Immunodeficiency Virus Co-Infection
|
Phase 3 | |
Completed |
NCT02609659 -
Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Low-Dose Ribavirin QD in Subjects With Genotype 1a Chronic Hepatitis C Virus Infection
|
Phase 3 | |
Completed |
NCT04352309 -
Efficacy Study Of Oral Glecaprevir/Pibrentasvir Tablet In Pediatric (12 Years and Older) And Adult Treatment-Naive Participants With Chronic Hepatitis C Genotypes 1 To 6 And Liver Cirrhosis
|
||
Completed |
NCT03069365 -
A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection and Renal Impairment
|
Phase 3 | |
Completed |
NCT01754974 -
Safety and Efficacy Study of Peginterferon Lambda-1a vs. Peginterferon Alfa-2a, Plus Ribavirin in Subjects With Genotype 1 Hepatitis C
|
Phase 3 | |
Withdrawn |
NCT01447394 -
Safety and Efficacy Study of Pegylated Interferon Lambda Versus Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C
|
Phase 3 | |
Completed |
NCT03067129 -
A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection
|
Phase 2/Phase 3 | |
Completed |
NCT03219216 -
A Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults in Brazil With Chronic Hepatitis C Virus (HCV) Genotype 1 - 6 Infection
|
Phase 3 | |
Completed |
NCT02517515 -
ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Treatment-Naïve and Treatment-Experienced, Non-Cirrhotic Asian Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection
|
Phase 3 | |
Completed |
NCT01616524 -
Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3
|
Phase 3 | |
Completed |
NCT02966795 -
A Study of of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection
|
Phase 3 | |
Completed |
NCT04189627 -
A Study of the Effectiveness and Clinical Practice Use of Glecaprevir/Pibrentasvir in Adolescents With Chronic Hepatitis C Genotypes 1 to 6 in Russian Federation
|
||
Completed |
NCT03341871 -
Glecaprevir/Pibrentasvir Drug Use Results Survey in Patients Infected With Hepatitis C Virus Genotype 1-6
|
||
Recruiting |
NCT04214028 -
A Study of the Safety, Effectiveness and Clinical Use of Maviret in Adolescent Patients With Chronic Hepatitis C Virus
|
||
Completed |
NCT03212521 -
Efficacy and Safety of 8-weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve Adults With HCV Genotype 1-6 and Aspartate Aminotransferase to Platelet Ratio Index (APRI) ≤1
|
Phase 3 | |
Active, not recruiting |
NCT04903626 -
Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB)
|
Phase 3 | |
Completed |
NCT03201718 -
A Study of Viekira/Exviera for Korean Hepatitis C Patients According to the Standard for Re-examination of New Drugs
|